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Abstract
The goal of elimination of the human filariases would benefit greatly from the use of a macrofilaricidal agent. In vivo trials in
humans and many experimental animal models suggest that flubendazole (FLBZ) is a highly efficacious macrofilaricide.
However, since serious injection site reactions were reported in humans after parenteral FLBZ administration, the search for
alternative pharmaceutical strategies to improve the systemic availability of FLBZ and its metabolites has acquired urgency
in both human and veterinary medicine. The goal of the current work was to compare the systemic exposure of FLBZ
formulated as either an aqueous hydroxypropyl-b-cyclodextrin (CD) or aqueous carboxymethyl cellulose (CMC) suspension
or a Tween 80-based formulation (TWEEN) in rats and jirds (Meriones unguiculatus). Healthy animals of both species were
allocated into four experimental groups of 44 animals each: FLBZ-CDoral and FLBZ-CDsc, treated with the FLBZ-CD
formulation by the oral or subcutaneous routes, respectively; FLBZ-TWEENsc, dosed subcutaneously with the FLBZ-TWEEN
formulation; and FLBZ-CMCoral, treated orally with the FLBZ suspension. The FLBZ dose was 5 mg/kg. FLBZ and its
hydrolyzed (H-FLBZ) and reduced (R-FLBZ) metabolites were recovered in plasma samples collected from rats and jirds
treated with the different FLBZ formulations. In both species, FLBZ parent drug was the main analyte recovered in the
bloodstream. In rats, FLBZ systemic exposure (AUC0-LOQ) was significantly (P,0.05) higher after the FLBZ-CD treatments,
both oral (4.860.9 mg.h/mL) and subcutaneous (7.360.6 mg.h/mL), compared to that observed after oral administration of
FLBZ-CMC suspension (0.9360.2 mg.h/mL). The same differences were observed in jirds. In both species, parenteral
administration of FLBZ-TWEEN did not improve the systemic availability of FLBZ compared to FLBZ-CDoral treatment. In
conclusion, formulation approaches that enhance the availability of flubendazole in the rat and jird may have therapeutic
implications for a drug with poor or erratic bioavailability.
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Introduction
Lymphatic filariasis and onchocerciasis are tropical parasitic
diseases caused by filarial nematodes in the superfamily Filarioidea,
also known as ‘‘filariae’’. Filariasis constitutes a serious public
health issue in tropical regions. Approximately 128 million
individuals suffer from lymphatic filariasis (commonly known as
elephantiasis), mainly in Africa and South-East Asia. The disease
causes debilitating lymphedema and hydrocele, resulting in
temporary or permanent disability, impairment of physical
productivity, income loss and social stigma [1]. Onchocerciasis
[also known as river blindness) afflicts approximately 26 million
individuals in Africa, where an estimated 746,000 are visually
impaired and 265,000 are blinded by the disease, constituting one
of the leading causes of blindness in the world [1–2]. Lymphatic
filariasis is caused by Wuchereria bancrofti, Brugia malayi and Brugia
timori, while Onchocerca volvulus is the cause of river blindness.
Infective larvae of filariae are transmitted by blood-feeding insects,
developing into fertile adults several months after infection.
Chronic, long-term infections occur through suppression of host
immunity [2].
Current control programs rely on three drugs, which are safe
and available through donation: diethylcarbamazine (DEC),
ivermectin (IVM), and albendazole (ABZ). DEC kills larval stages
in the host (microfilaria) and provides long-term sterility of adults,
with limited adulticidal efficacy in the regimens employed. It is
contraindicated in areas where onchocerciasis is endemic, due to
potentially serious and unacceptable side effects affecting the eyes
and the skin of infected persons [2] as well as in pregnancy [3].
IVM is a microfilaricide and also provides long-term sterilization
of adult worms, preventing re-population of the host with
microfilariae for 6 months or longer, but needs to be given at
least annually [4]. Like DEC, IVM has limited macrofilaricidal
effects in humans or other animals, which greatly prolongs the
time required for mass drug administration programs to progress
to eradication [5]. Lastly, ABZ is routinely included with annual
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treatments of DEC or IVM in lymphatic filariasis control
programs. Nevertheless, the activity of the benzimidazole compo-
nent (ABZ) in this regimen is uncertain, and whether combination
therapy confers benefits over DEC or IVM alone remains
controversial [5]. Thus, the control of human filarial infections
currently depends on strategies predominantly focused on killing
microfilariae and the long-term cessation of their production [6]. It
is now generally recognized that the success of filariasis control
programs in a reasonable time-frame would be favored by the
addition of a macrofilaricidal compound to current control
strategies [4,6,7].
Flubendazole (FLBZ), a methylcarbamate benzimidazole
(BZD), is highly active against a broad spectrum of gastrointestinal
nematodes in humans and some animal species. FLBZ has also
demonstrated a marked lethal effect on many filarial species in
animal model hosts [6]. FLBZ has been reported to be the best
macrofilaricidal molecule within the BZD group [8]. This
compound is already approved for use in humans [9], which
may be an advantage over other candidates for filariasis. FLBZ,
like other BZDs, has limited water solubility and is commercially
available for oral administration in humans as tablets or
suspensions, providing low systemic bioavailability [10]. The
macrofilaricidal activity of FLBZ is thought to require sustained
systemic exposure, which is not achieved after administration of
conventional oral formulations. The in vivo activity of FLBZ
against a variety of filariid species has been reported after its
parenteral administration in animal and human trials [6,11–12].
FLBZ was available as a sterile suspension for intramuscular
treatment [13]; however, since serious injection site reactions were
reported in humans after parenteral FLBZ administration [12],
the search for alternative pharmaceutical strategies to improve
systemic availability of FLBZ after oral dosing has acquired
urgency in both human and veterinary medicine.
Several pharmacotechnical strategies have been explored to
enhance BZD systemic bioavailability. Cyclodextrins (CD), cyclic
oligosaccharides used to increase drug solubility, are well-known
molecular hosts capable of including water-insoluble guest
molecules via non-covalent interaction within a hydrophobic
cavity [14]. Enhanced aqueous solubility and bioavailability of
guest molecules is a common effect observed after drug
formulation with CD [15]. We have previously reported that
incorporation of FLBZ into a hydroxypropyl-b-cyclodextrin (CD)
formulation significantly increased its water solubility [16] and
systemic exposure in mice by more than 25-fold compared to the
conventional FLBZ suspension [17]. The relative bioavailability of
albendazole sulphoxide (ABZSO) in mice was also increased by
formulation with a CD [18]. Similar findings have been reported
in humans [19].
The goal of the current study was to compare the plasma
pharmacokinetic behaviour and systemic exposure of FLBZ
formulated as either an aqueous CD-based solution (FLBZ-CD),
aqueous carboxymethylcellulose (CMC) suspension (FLBZ-CMC)
or a Tween 80-based formulation (FLBZ-TWEEN) in non-
infected jirds (Meriones unguiculatus) and rats.
Methods
Chemicals
Pure reference standards of FLBZ, reduced-FLBZ (R-FLBZ)
and hydrolyzed-FLBZ (H-FLBZ) used to develop the analytical
methodology were kindly provided by Janssen Animal Health
(Beerse, Belgium). Oxibendazole (OBZ), used as internal standard,
was obtained from Schering Plough (Kenilworth, NJ, USA).
HPLC grade acetonitrile and methanol were from Sintorgan S.A.
(Buenos Aires, Argentina) and J.T. Baker (New Jersey, USA),
respectively. HPBCDs were from ISP Pharmaceuticals (Cavasol,
Cavitron, New Jersey, USA). Low viscosity grade sodium CMC
was purchased from Anedra (Buenos Aires, Argentina). Tween 80
was purchased from Biopack (Buenos Aires, Argentina).
Preparation of FLBZ formulations
The FLBZ CD-based solution was prepared by dissolving FLBZ
(0.1%) and CD (10%) in deionized water. The pH of the
formulation was adjusted to 1.2 using hydrochloric acid (25 mM).
The formulation was shaken until total dissolution of the drug and
then was filtrated through a 0.45 mm filter (Whatman, NJ, USA).
The final FLBZ concentration was confirmed by HPLC (n = 4).
Cavitron and Cavasol were the CD used in formulations intended
for oral and parenteral administration, respectively. The Tween
80-based formulation was prepared by dissolving FLBZ (0.25%) in
Tween 80. The FLBZ-suspension was prepared by addition of
FLBZ (0.1%) and CMC (0.1%) in deionized water (pH = 6.0) with
shaking for 6 h. The FLBZ- CMC suspension was vigorously
shaken immediately before intragastric administration to jirds and
rats. FLBZ formulations were freshly prepared and maintained
under refrigeration (3–5uC).
Experimental animals
Ethics statement. One hundred and seventy six (176)
healthy jirds (approx. 50 g) and the same number of Wistar rats
(approx. 200 g) were housed in a controlled temperature
(2162uC), light-cycled (12 h light/dark cycle) room. Food and
water were provided ad libitum. Animal procedures and manage-
ment protocols were approved by the Ethics Committee according
to the Animal Welfare Policy (act 087/02) of the Faculty of
Veterinary Medicine, Universidad Nacional del Centro de la
Provincia de Buenos Aires (UNCPBA), Tandil, Argentina (http://
Author Summary
Lymphatic filariasis and onchocerciasis are tropical para-
sitic diseases caused by filarial nematodes, which consti-
tute a serious public health issue in tropical regions.
Lymphatic filariasis causes debilitating lymphedema and
hydrocele, resulting in temporary or permanent disability.
Onchocerciasis (also known as river blindness) causes
visual impairment and blindness, constituting one of the
leading causes of blindness in the world. The control of
human filarial infections currently depends on strategies
predominantly focused at killing microfilariae (larval stage)
by the use of ivermectin or diethylcarbamzine, usually in
combination with albendazole. It is now generally recog-
nized that the success of filariasis control programs in a
reasonable time-frame requires the addition of a macro-
filaricide (adult stage) compound. Although flubendazole
has demonstrated macrofilaricidal activity in vivo, the
approved formulations provide almost no oral bioavail-
ability. The search for alternative pharmaceutical strategies
to improve the systemic availability of flubendazole has
acquired urgency in both human and veterinary medicine.
Searching for improved flubendazole absorption, different
flubendazole pharmaceutical preparations were assessed,
both in rats and jirds, in the study described here. The
work demonstrated that flubendazole pharmacokinetics
could be markedly modified by changes in drug formu-
lation. The resulting improved systemic exposure of
flubendazole may have a significant impact on its
macrofilaricidal efficacy.
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www.vet.unicen.edu.ar) and followed the Guide for the Care and
Use of Laboratory Animals (National Research Council, Wash-
ington DC, National Academy Press, 2011) [20].
Experimental design. Jirds and rats were randomly allocat-
ed into four experimental groups (44 animals each). Experimental
animals received the following treatments: FLBZ-CDoral, dosed
orally (administered volume 0.25 and 1 mL for jirds and rats,
respectively) in a CD-based solution (Cavasol); FLBZ-CDsc, dosed
subcutaneously (sc) (injection volume of 0.25 and 1 mL for jirds
and rats, respectively) in a CD-based solution (Cavitron); FLBZ-
TWEEN, dosed sc (injection volume of 0.1 and 0.4 mL for jirds
and rats, respectively) in a Tween-based formulation; and FLBZ-
CMC, dosed orally (same volume as for FLBZ-CDoral) in a CMC-
based suspension. The oral dose was administered using an
intragastric tube. All treatments were given as a single dose of
5 mg/kg. The dose was selected because it is the dose previously
reported in efficacy studies performed in the murine model [17].
At defined time-points following treatment (5, 15 and 30 min, 1, 2,
3, 4, 6, 9, 12 and 16 h), blood samples were collected (n = 4 per
time point) in heparinized plastic tubes. Plasma was separated by
centrifugation at 20006g for 15 min, placed into plastic tubes and
frozen at 220uC until analysis by HPLC to quantify FLBZ, R-
FLBZ and H-FLBZ plasma concentrations. After sc administra-
tion of the formulations, potential injection site reactions were
evaluated by direct visual observation at the sampling time.
Analysis of FLBZ and its metabolites
Chromatography was performed on a Shimadzu HPLC
platform (Shimadzu Corporation, Kyoto, Japan), with two LC-
10AS solvent pumps, an automatic sample injector (SIL-10A) with
a 50 mL loop, an ultraviolet-visible spectrophotometric detector
(UV) (SPD-10A) reading at 292 nm, a column oven (Eppendorf
TC-45, Eppendorf, Madison, WI, USA) set at 30uC, and a CBM-
10A integrator. Data and chromatograms were collected and
analyzed using the Class LC10 software (SPD-10A, Shimadzu
Corporation, Kyoto, Japan). The C18 reversed-phase column
(5 mm, 250 mm64.6 mm) was Kromasil (KromasilH, Sweden).
Elution from the stationary phase was carried out at a flow rate of
1.2 mL/min using an acetonitrile (34%)/ammonium acetate
buffer (0.025 M, pH 5.3, 66%) as a mobile phase.
Plasma samples (100 or 200 mL for jirds and rats, respectively)
were spiked with OBZ as internal standard. After 5 min, plasma
samples were mixed with water up to 1 mL and the analytes were
extracted using disposable C18 cartridges (Strata, Phenomenex,
CA, USA) as previously described [17]. Identification of FLBZ
and its metabolites was undertaken by comparison with the
retention times of pure reference standards. Complete validation
of the analytical procedures for extraction and quantification of
drug and metabolites in plasma was performed before starting the
analysis of experimental samples. Retention times for H-FLBZ, R-
FLBZ and FLBZ were 5.7, 7.1 and 14.4 min, respectively. The
calibration curves for each analyte, constructed by least squares
linear regression analysis, showed good linearity with correlation
coefficients $0.998. The limit of quantification (FLBZ and
metabolites was 0.01 mg/mL), defined as the lowest measured
concentration with a CV ,20%, accuracy of 620% and absolute
recovery $70%.
Pharmacokinetic analysis of the data
The peak concentration (Cmax) and time to peak concentration
(Tmax) were read from the plotted concentration–time curve for
each analyte. The area under the concentration–time curve from 0
up to the limit of quantification (AUC0-LOQ) for FLBZ and
metabolites was calculated by the trapezoidal rule [21], using the
PKSolutionTM computer program (Summit Research Services,
Ashland, OR, USA).
Statistical analysis
PK parameters are presented as arithmetic means 6 SD. Non-
parametric (Mann-Whitney) tests were used for statistical com-
parison of the pharmacokinetic data obtained from the experi-
mental groups in each animal species. A value of P,0.05 was
considered statistically significant. Statistical analysis was per-
formed using the Instat 3.0 Software (Graph Pad Software, CA,
USA).
Results
No local tissue effects were observed in either species after sc
administration of FLBZ formulated with either CD- or Tween 80.
Figures 1 and 2 show mean plasma concentrations of FLBZ and
metabolites after sc administration (5 mg/kg) of FLBZ in a CD-
based formulation (FLBZ-CDsc) to rats and jirds, respectively.
FLBZ and H-FLBZ were the main molecules detected in plasma
of FLBZ-treated rats and jirds. Low R-FLBZ concentrations were
detected between 15 min and 12 h post-treatment, with AUC0-
LOQ values about 10% of the total drug recovered from plasma in
the different groups for both species. FLBZ and H-FLBZ
concentrations rapidly increased to reach peak plasma concentra-
tions, observed as early as 0.7–3.2 h (FLBZ) and 3.0–5.2 h (H-
FLBZ), according the experimental group and animal species.
The comparative plasma concentration profiles of FLBZ
obtained after oral or sc administration as different formulations
to rats, along with some pharmacokinetic parameters (Cmax and
AUC0–LOQ), are shown in Figure 3. Table 1 summarises the
plasma pharmacokinetics parameters (Cmax, Tmax and AUC0-
LOQ) for FLBZ and H-FLBZ obtained after oral or sc adminis-
tration of the FLBZ formulations to rats. Higher drug systemic
exposure was obtained after administration of FLBZ as a CD or
Tween 80-based formulation to rats compared to the CMC-based
suspension, resulting in significantly higher Cmax and AUC0–LOQ
values for both FLBZ H-FLBZ in the FLBZ-CDoral, FLBZ-CDsc
and FLBZ-TWEEN groups (Table 1).
The sc administration of FLBZ-CDsc to rats improved its
systemic exposure, resulting in significantly higher AUC0-LOQ
values compared to all other experimental groups (Table 1).
Additionally, FLBZ was detected in plasma for longer period (up
to 16 h post-treatment) after parenteral administration (FLBZ-
CDsc and FLBZ-TWEEN).
The administration of FLBZ as a Tween 80-based formulation
to rats did not improve its systemic availability compared to oral
administration of FLBZ-CDoral. Similar FLBZ AUC0-LOQ values
were observed in the FLBZ-CDoral and FLBZ-TWEEN groups. In
these groups, no differences were observed in either Cmax or
AUC0-LOQ values obtained for H-FLBZ (Table 1).
Unlike rats, neither H-FLBZ nor R-FLBZ was detected in
plasma at any time post-treatment of jirds with FLBZ-CMC. Only
trace amounts of FLBZ were detected, and only over a period so
short that it precluded pharmacokinetic analysis. However,
treatment with either FLBZ-CD (oral or sc routes) or FLBZ-
TWEEN solutions allowed quantification of FLBZ and its reduced
and hydrolyzed metabolites in jirds. Similar to rats, FLBZ was the
main analyte detected in plasma, whereas H-FLBZ concentrations
represented 10–20% of the total amount of drug recovered, with
even lower R-FLBZ concentrations in jirds (Figure 2). The
comparative plasma concentration profiles (mean6 SD) for FLBZ
after administration as CD- or Tween 80-based formulations are
shown in Figure 4. Table 2 summarizes the main pharmacokinetic
Potencial of Flubendazole in Filariasis Control
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parameters obtained for FLBZ after oral (FLBZ-CDoral) or sc
(FLBZ-CDsc and FLBZ-TWEEN) administration to jirds. The sc
treatment with the Tween 80-based formulation did not improve
FLBZ systemic exposure compared to FLBZ-CDoral; similar
AUC0-LOQ and Cmax values were obtained in both groups
(Table 2). However, FLBZ absorption in the FLBZ-TWEEN
group was slower compared to sc and oral FLBZ-CD groups, since
a significantly longer Tmax was observed in that group.
Interestingly, FLBZ-CDsc delivered an enhanced FLBZ Cmax
value (90–130%) compared to FLBZ-CDoral and FLBZ-TWEEN.
A similar trend was observed in AUC0-LOQ values, but high
individual variability may have obscured detection of statistically
significant differences in this pharmacokinetic parameter among
groups. Comparison of the relative contribution of FLBZ, H-
FLBZ and R-FLBZ to the total drug plasma concentrations
quantified after FLBZ treatment in different animal species,
including rats, jirds, mice, pigs and sheep, is shown in Figure 5.
Discussion
When pharmacological research cannot be done on humans for
practical and ethical reasons, animal models constitute a practical
approach to understand the parasite-active drug-host relationship.
In the current work, two different animal models (rat and jird)
were used to approximate what might be expected in humans. The
overall plasma pharmacokinetic behaviour of BZD anthelmintics
in humans is similar to other monogastric species such as mice or
rats, and greatly differs from what has been reported in ruminant
species (sheep, cattle). In ruminants, the rumen acts as a drug
reservoir, and slowing the digesta transit time results in improved
systemic availability as a consequence of greater dissolution of
drug particles in the acidic pH of the abomasum (the stomach)
[22]. The briefer gut transit time in monogastric species allows a
shorter time for dissolution of the drug suspension compared to
ruminants, limiting gastrointestinal absorption of the drug. Thus,
rats or jirds could be valid animal models to obtain kinetic data
extrapolatable to humans, particularly when systemic exposure of
BZD anthelmintics is evaluated after the administration of
different formulations. Additionally, jirds have been extensively
used as animal models in drug screening studies for potential
antifilarial compounds [8,11]. Thus, the basic pharmacokinetic
data reported here could be linked to efficacy trials against filarial
nematodes in the same animal model.
Three main factors play important roles in activity against
nematodes: i. attaining sufficient drug concentrations at the site of
target parasite location to be able to therapeutically affect
Figure 1. Rat. Mean (6 SD) plasma concentrations of flubendazole (FLBZ) and its reduced (R-FLBZ) and hydrolyzed (H-FLBZ) metabolites following
subcutaneous (sc) administration of FLBZ-CD solution (5 mg/kg) to uninfected rats (n = 4 per time point).
doi:10.1371/journal.pntd.0002838.g001
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receptors in parasites [23]; ii. drug lipophilicity [22]; and iii.
physicochemical features of the tissue/fluids surrounding the
parasite [24]. Drug concentration at the site of parasite location
depends on the chemical properties of the drug and the
pharmaceutical preparations in which the active compound is
formulated. Therapeutic failures observed in parasite control in
both human and veterinary medicine may be related to exposure
of parasites to sub-therapeutic drug concentrations due to poor
drug dissolution and/or insufficient systemic availability of the
active ingredient. Obtaining adequate drug concentrations in the
compartment in which the parasite resides is a key factor that
determines efficacy against systemic parasites. The physicochem-
ical features of the parasite environment play a pivotal role in
determining drug access and accumulation. Some nematode
parasites living in host tissues may be protected from the
deleterious effect of an anthelmintic due to low diffusion of
lipophilic compounds. Furthermore, the low water solubility of
BZD anthelmintics seriously limits their absorption and systemic
bioavailability. Clearly, the poor oral absorption of FLBZ after
administration in the conventional suspension/tablet formulations
is a serious disadvantage for the treatment of systemic infections
such as filariasis. Low FLBZ bioavailability has been associated
with low in vivo activity against cystic echinococcosis in mice [17].
The use of pharmacotechnical strategies to overcome this
limitation may markedly improve the in vivo efficacy of FLBZ
against systemic parasitic nematodes.
The lack of water solubility is an important limitation for the
formulation of the most potent BZD methylcarbamate anthelmin-
tics, such as FLBZ. Irritation and post-injection precipitation are
concerns in parenteral drug delivery for poorly water-soluble drugs
[25]. The greater water solubility of the main active albendazole
metabolite, albendazole sulphoxide (also named ricobendazole),
was the starting point in the development of an injectable
formulation for use in cattle currently available in some Latin
American countries [26]. However, since BZD aqueous solubility
is markedly higher at low pH values [27], that formulation
contains ricobendazole (15% final concentration) at low pH
(approx. 1–2), which produces irritation at the site of sc
administration. Recently, a CD-based formulation of ricobenda-
zole for parenteral use has demonstrated adequate tissue
tolerability and bioavailability [25], but is not available in the
veterinary market. Complexation with cyclodextrins has been
intensively investigated as a solubilization approach for parenteral
formulations. In agreement with our recent results, cyclodextrin
formulations of poorly water-soluble drugs have shown little or no
tendency for drug precipitation after intramuscular injection [25].
Figure 2. Jird. Mean (6 SD) plasma concentrations of flubendazole (FLBZ) and its reduced (R-FLBZ) and hydrolyzed (H-FLBZ) metabolites following
subcutaneous (sc) administration of FLBZ-CD solution (5 mg/kg) to uninfected jirds (n = 4 per time point).
doi:10.1371/journal.pntd.0002838.g002
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Figure 3. Flubendazole rat. Comparative flubendazole (FLBZ) mean (6 SD) plasma concentration profiles obtained after administration of
different formulations to uninfected rats (n = 4 per time point). Insert shows the pharmacokinetic parameters AUC 0-t and Cmax (mg/mL) estimated for
FLBZ. Different letters indicate statistically significant differences (P,0.05) between experimental groups.
doi:10.1371/journal.pntd.0002838.g003
Table 1. Pharmacokinetic parameters (mean 6 SD) obtained for flubendazole (FLBZ) and its hydrolyzed metabolite (H-FLBZ) after
treatment (5 mg/kg) with different FLBZ formulations to uninfected rats: Cyclodextrin-based (FLBZ-CDoral or FLBZ-CDsc), Tween-
based (FLBZ-TWEEN) and carboxy methylcellulose-based (FLBZ-CMC).
Pharmacokinetic parameters FLBZ
FLBZ-CDoral FLBZ-CDsc FLBZ-TWEENsc FLBZ-CMCsc
Cmax (mg/mL) 2.3460.75a 1.5160.29a 0.6060.07b 0.1460.01c
Tmax (h) 0.8760.75a 0.7060.35a 2.5061.00a 3.2561.50a
AUC0-LOQ (mg.h/mL) 4.8060.86
a 7.3260.59b 4.0060.80a 0.9360.16c
H-FLBZ
Cmax (mg/mL) 0.7260.39a 0.5060.06a 0.5660.07a 0.1260.01b
Tmax (h) 3.2560.50a 5.2562.87a 5.0061.15a 3.0061.41a
AUC0-LOQ (mg.h/mL) 4.3761.37
a 5.1560.75a 5.3260.41a 0.5160.27c
Cmax: peak plasma concentration; Tmax: time to peak plasma concentration; AUC0-LOQ: area under the concentration vs. time curve from 0 up to the limit of
quantification. Different letters indicate statistically significant differences (P,0.05) between experimental groups.
doi:10.1371/journal.pntd.0002838.t001
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It is worth noting that most of the progress achieved to improve
bioavailability of BZDs has been in formulation design [18,28–29].
Prospects for an accelerated path to the elimination of
onchocerciasis and lymphatic filariasis would be much enhanced
if a safe and effective macrofilaricide were available [5,6,7].
Therefore, improvement of FLBZ systemic availability was the
essential component under evaluation in the current work. We
have previously reported that CDs markedly increase FLBZ water
solubility [16], which was correlated with enhanced systemic drug
exposure in mice [17], as demonstrated by significantly higher
plasma Cmax (28 fold-higher) and AUC (27 fold-higher) values
compared to a conventional suspension. Moreover, the efficacy of
FLBZ against cystic echinococcosis in mice was also dramatically
improved after oral administration of a CD-based formulation
[17,30]. Similar pharmacokinetic results were obtained for ABZ in
mice [18,30] and humans [19], in which a significantly higher
systemic exposure for ABZ-sulphoxide was observed after ABZ
administration in a CD-based solution. Consistent with previous
data, the CD-based formulations FLBZ-CDoral and FLBZ-CDsc
significantly increased FLBZ systemic exposure in rats compared
to the FLBZ-CMC formulation. Similar FLBZ AUC0-LOQ values
were observed between the FLBZ-CDoral and the Tween 80-based
sc formulations. The highest FLBZ relative plasma availability was
attained in the FLBZ-CDsc group, in which the AUC0-LOQ value
increased by 684% compared to that observed after the oral
administration of the FLBZ-CMC suspension. The FLBZ plasma
detection period (up to 16 h post-treatment) was similar among the
CD- and Tween 80-based formulations. CDs have the ability to
complex with drugs, affording increased water solubility and
improved oral bioavailability of FDA Class II compounds (poor
aqueous solubility, high permeability) [15], such as the BZD
anthelmintics. In the current work, the CD-based formulation
induced drastic changes in FLBZ aqueous solubility, which accounted
for its enhanced absorption and systemic availability in rats.
Interestingly, neither FLBZ nor its metabolites were detected in
plasma after FLBZ-CMC treatment in jirds. Similar FLBZ plasma
AUC0-LOQ values were observed among FLBZ-CD oral or sc
treatments and the FLBZ-TWEEN groups. The H-FLBZ and R-
FLBZ metabolites were recovered in plasma, although in much
lower concentrations than the parent drug. In agreement with
kinetic data obtained in rats, high FLBZ peak plasma concentra-
tions were observed after sc administration as a CD-solution
compared to the Tween 80 sc formulation. As previously
mentioned, CD clearly improves FLBZ absorption in jirds after
both oral or sc treatment. It is generally accepted that CDs enhance
drug permeability by solubilizing their lipophilic components,
thereby disrupting barriers to diffusion and increasing permeability.
CDs may also act as permeation enhancers by carrying the drug in
inclusion complexes through the aqueous barrier, from the bulk
solution towards the surface of biological membranes [31].
Figure 4. Flubendazole jird. Comparative flubendazole (FLBZ) mean (6 SD) plasma concentration profiles obtained after administration of
different formulations to uninfected jirds (n = 4 per time point). Insert shows the pharmacokinetic parameters AUC 0-t and Cmax (mg/mL) estimated for
FLBZ parent drug. Different letters indicate statistically significant differences (P,0.05) between experimental groups.
doi:10.1371/journal.pntd.0002838.g004
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Dominguez-Vazquez et al. [12] demonstrated that an injectable
formulation of FLBZ was highly efficacious in humans against
adult O. volvulus. Parenteral administration of a FLBZ Tween 80-
based formulation has high efficacy against multiple filarial species
in several animal hosts [6–8]. Since FLBZ plasma exposure
obtained in the FLBZ-CDoral and FLBZ-CDsc groups was greater
than obtained in the FLBZ-TWEEN group, high macrofilaricidal
efficacy of the CD-based formulations may be possible. However,
the potential of those formulations for treatment of humans may
be limited by the high cost of the CD used in the formulation
assessed in the current experimental work (hydroxyl propyl b-
cyclodextrin).
Table 2. Pharmacokinetic parameters (mean6 SD) obtained for flubendazole (FLBZ) after its administration (5 mg/kg) as different
formulations to uninfected jirds: Cyclodextrin-based (FLBZ-CDoral or FLBZ-CDsc) and Tween-based (FLBZ-TWEEN) formulations.
Pharmacokinetic parameters FLBZ
FLBZ-CDoral FLBZ-CDsc FLBZ-TWEENsc
Cmax (mg/mL) 1.0860.17a 2.1960.48b 0.8960.29a
Tmax (h) 1.1560.98a 0.8260.78a 2.2561.50b
AUC0-LOQ (mg.h/mL) 4.5760.99
a 6.7762.04a 4.3261.17a
Cmax: peak plasma concentration; Tmax: time to peak plasma concentration; AUC0-LOQ: area under the concentration vs. time curve from 0 up to the limit of
quantification. Different letters indicate statistically significant differences (P,0.05) between experimental groups.
doi:10.1371/journal.pntd.0002838.t002
Figure 5. Relative systemic exposure (area under concentration vs. time curve, AUC 0-t) of flubendazole (FLBZ) and its reduced (R-
FLBZ) and hydrolyzed (H-FLBZ) metabolites in different animal species treated orally with a FLBZ-CD solution. Data taken from
Ceballos et al, 2009 (1), 2012 (a) (2), 2012 (b) (3).
doi:10.1371/journal.pntd.0002838.g005
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Unlike other commonly used BZD anthelmintics, such as
albendazole (aliphatic substitution at position -5) and fenbendazole
(aromatic substitution at position -5), FLBZ contains a ketone
group in that position, which has implications for its metabolism
by the host. While sulphur-containing BZDs are sequentially
oxidised to their sulphoxide and sulphone metabolites by both
flavin-monooxygenase (FMO) and cytochrome P450 (P450)
systems in the liver [32–33], carbonyl reductases (CBRs) are
thought to be the main enzymes involved in FLBZ biotransfor-
mation [34]. The main FLBZ metabolic pathways include
reduction of the ketone group to form R-FLBZ, and hydrolysis
of the methylcarbamate group to form H-FLBZ. The contribution
of each metabolite to the total amount of drug recovered from
plasma after FLBZ treatment may vary among animal species. R-
FLBZ is the main metabolite measured in plasma after FLBZ
treatment in sheep [10,16] and mice [17,30] (Figure 5). However,
while low plasma concentrations of FLBZ are detected in sheep,
the parent compound was the main analyte in FLBZ treated mice.
A different pattern was observed in pigs treated with FLBZ, in
which H-FLBZ was the predominant molecule, representing 97%
of total drug measured in the bloodstream after FLBZ treatment
[35] (Figure 5). In rats, similar amounts of FLBZ and H-FLBZ
were present in the bloodstream, with only trace amounts of the
R-FLBZ metabolite. Although oral bioavailability of FLBZ has
been estimated in humans [9], no data are available on the
plasma pharmacokinetic pattern of FLBZ and metabolites.
However, in vitro studies performed in our lab have shown that
human microsomes biotransform FLBZ mainly to the R-FLBZ
metabolite (unpublished data), which suggests similarity with the
metabolic profile observed in mice and sheep (see Figure 4).
Species-related differences in plasma drug exposure observed
for FLBZ and metabolites may significantly influence drug
efficacy. While H-FLBZ is an inactive metabolite, biological
activity has been described for R-FLBZ [30,36–37], which may
contribute to anthelmintic efficacy observed after FLBZ
treatment.
The marked improvement of FLBZ systemic availability
observed after the administration of CD-based formulations to
rats and jirds needs to be considered in terms of its potential
usefulness as a macrofilaricide in animal models. If oral and/or
parenteral administration of FLBZ-CD formulations provides
satisfactory efficacy, the empirical correlation of plasma concen-
trations and efficacy may contribute to the development of new
formulations for use in humans. The work reported here indicates
that FLBZ plasma availability can be markedly improved by
changes in formulation. The enhanced systemic exposure observed
after treatment with the CD-based formulations has significant
therapeutic implications for a drug with poor or erratic
bioavailability.
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